SG/CALL/ELI LILLY & CO/300/0.1/21.06.24 | Market Closed - Deutsche Boerse AG 20:51:11 20/06/2024 BST | ||
| 54.57 EUR | -1.00% |
|
| Current month | +15.73% | ||
| 1 month | +26.77% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
ELI LILLY AND COMPANY
Latest news about ELI LILLY AND COMPANY
| Date | Price | Change |
|---|---|---|
| 20/06/24 | 54.57 | -1.00% |
| 19/06/24 | 55.12 | +0.49% |
| 18/06/24 | 54.85 | +0.24% |
| 17/06/24 | 54.72 | +1.26% |
| 14/06/24 | 54.04 | -0.07% |
Delayed Quote Deutsche Boerse AG
Last update June 20, 2024 at 08:51 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | CALL |
| Underlying | ELI LILLY AND COMPANY |
| Issuer | 
Société Générale
|
| WKN | SQ4JGR |
| ISIN | DE000SQ4JGR3 |
| Date issued | 17/11/2022 |
| Strike | 300 $ |
| Maturity | 21/06/2024 (1 Days) |
| Parity | 10 : 1 |
| Emission price | 9.59 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 55.76 € |
|---|---|
| Lowest since issue | 5.37 € |
Company Profile
Eli Lilly and Company is one of the world's leading pharmaceutical groups. Net sales break down by therapeutic field as follows:
- endocrinology (57.7%): products for treating osteoporosis, diabetes, and growth problems;
- oncology (19.5%);
- immunology diseases (11.1%);
- neurology (8.4%): primarily drugs used in treating depression and schizophrenia;
- other (3.3%).
Net sales are distributed geographically as follows: the United States (63.9%), Europe (18.1%), Japan (4.9%), China (4.5%) and other (8.6%).
Sector
-
Consensus: Eli Lilly and Company
Sell
Buy
Mean consensus
BUY
Number of Analysts
28
Last Close Price
886
USD
Average target price
855.4
USD
Spread / Average Target
-3.45%
- Stock Market
- Warrants
- Warrant
